Dovato (dolutegravir;lamivudine)
- Region
- 🇪🇺 EU
- Active substance
- dolutegravir;lamivudine
- Company
- ViiV Healthcare B.V.
- Status
- Authorised
- Therapeutic area
- HIV Infections
- CHMP opinion
- Fri 26 Apr 2019
- EU approval
- Mon 01 Jul 2019
- Application
- EMEA/H/C/004909
- ATC
- J05AR
- Official record
- www.ema.europa.eu
Indication
Dovato is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Triumeq Authorised · ViiV Healthcare B.V.
Follow Dovato
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.